Received a claim from a radiotherapy service.The physicians observed that the device is not allowing the therapy sessions to be done correctly to patients with breast cancer, since the port attenuate the treatment in the area, because of the tungsten or titanium, and those are leaving untreated areas.
|
On receipt of the complaint a literature search was performed by medcomp engineering and clinical.The articles found indicated the possibility that radiation therapy may be compromised due to the port components attenuating energy resulting in the patient not receiving the prescribed radiation dose and leaving untreated areas.However, the information in the reports are either non-clinical or based on simulations, phantom studies.The reports did not indicate if the issue affects patient clinical outcomes.It is unknown if the patient survival rate is changed if the port blocks or affects the radiation therapy.Ports are placed in cancer patients to provide an access to deliver drugs.It is unlikely that the port would be implanted in the patient in a location near the cancer.If it was implanted over the area of radiation, the size of the port is unlikely to significantly block the radiation therapy.In addition, the physician would be aware of the location of the port and adjust the therapy to compensate for the port.Medcomp has been manufacturing and selling ports for over 10 years.This is the first report of this nature for any medcomp port.The conclusion reached is that there is no product failure or labeling issue.No actions will be taken at this time.
|